Document:

EX-10.17

 Exhibit 10.17 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 
 SECOND AMENDMENT TO LICENSE AGREEMENT 

This amendment to the License Agreement (the “Second Amendment”), effective on the date last signed below (“Effective Date”), is by and
between Avedro, Inc, a corporation having a place of business at 230 Third Ave, Waltham, MA 02451 (“Avedro”), and California Institute of Technology, a
not-for-profit corporation duly organized and existing under the laws of the State of California with an address at 1200 East California Boulevard, MC 6-32, Pasadena, California 91125 (“Caltech”; Avedro and Caltech together are the “Parties”). 

Whereas, the Parties entered into that certain License Agreement, effective February 19th, 2015 (the “License Agreement”); 

Whereas, the Parties made a first amendment and restatement of the License Agreement, effective July 31st, 2017 (“First Amendment”); and 

Whereas, the Parties desire to further amend the License Agreement as set forth in this Second Amendment. 

Now therefore, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, the Parties agree as follows: 
  

	1.	 Sections 8.1 through 8.5 are hereby deleted in their entirety and replaced with the following:

 8.1 Enforcement. Both Caltech and Licensee agree to promptly notify the other in writing
should either Party become aware of possible infringement by a third party of the Exclusively Licensed Patent Rights in the Field. Caltech shall also notify The Regents. 
  

  
 Page 1 of 6

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 Upon notice and exchange of evidence of such infringement, Licensee and
Caltech shall meet and confer to discuss how best to proceed with enforcement. During that meeting, Licensee may request that Caltech take steps to enforce the Exclusively Licensed Patent Rights. Pursuant to the terms of the IIA with The Regents,
Caltech shall first, in cooperation with The Regents, use its best efforts to terminate such infringement without litigation. If such efforts are unsuccessful and if Caltech does not, within [***] of Licensee’s request, elect to file an action
against the alleged infringer in the Field, Licensee will have all rights required by law to initiate an enforcement action in Licensee’s name at Licensee’s expense. Licensee shall be entitled to control any such action initiated by it,
but will keep Caltech apprised of the status of such action or suit, and will consult with Caltech should any issues arise in litigation that may be impactful to Caltech and/or other Caltech licensees. If Caltech is required by law to join in such
an action, or is subject to discovery requests in such an action, it will do so provided that: (a) Caltech will be represented by outside counsel of its choice; and (b) Licensee shall reimburse Caltech for all reasonable out-of-pocket expenses (including Caltech’s outside counsel) and all internal Caltech expenses in connection with the action. Licensee may take appropriate action to
terminate or prevent the infringement provided, however, that Licensee may not bring an action or enter into a settlement agreement with an accused infringer without prior written approval of Caltech, where reasonable approval will not be withheld.
In no event may The Regents be joined in any suit without its prior written consent. 

  
 Page 2 of 6

 8.2 Other Defensive Litigation. If a declaratory judgment
action alleging invalidity, unenforceability or non-infringement of any of the Exclusively Licensed Patent Rights is brought against Licensee and/or Caltech, Caltech shall have the first right to control the
defense of such action at ‘its own expense. Licensee may elect to control the defense of such action if Caltech declines to do so, and if Licensee so elects it shall bear all the costs of the action and shall make settlements only with the
advice and written consent of Caltech. If mutually agreed between the Parties, Licensee may also undertake the defense of any interference, opposition or similar procedure with respect to the Exclusively Licensed Patent Rights, providing that
Licensee bears all the costs thereof and makes settlements only with the advice and written consent of Caltech. 
 8.3
Cooperation. In the event either Party takes control of a legal action or defense pursuant to Sections 8.1 or 8.2 (thus becoming the Controlling Party), the non-controlling Party shall fully cooperate with and supply all assistance
reasonably requested by the Controlling Party, including by: (a) using commercially reasonable efforts to have its employees consult and testify when requested; (b) making available relevant records, papers, information, samples,
specimens, and the like; and (c) joining any such action in which it is an indispensable or necessary party. The Controlling Party shall bear the reasonable expenses (including salary and travel costs) incurred by the non-controlling Party in providing such assistance and cooperation. The Controlling Party shall keep the non-controlling Party reasonably informed of the progress of the
action or defense. If the non-controlling Party is not required by law to join the action, that Party shall nevertheless be entitled to participate in such action or defense at its own expense and using
counsel of its choice. As a condition of controlling any action or defense involving the Exclusively Licensed Patent Rights pursuant to Sections 8.1 or 8.2, Licensee shall use its best efforts to preserve the validity and enforceability thereof.

  
 Page 3 of 6

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 8.4 Settlement. If Licensee controls any action or defense
under Section 8.1 or 8.2, then Licensee shall have the right to settle any claims thereunder, but only upon terms and conditions that are reasonably acceptable to Caltech. Should Licensee elect to abandon such an action or defense other than
pursuant to a settlement with the alleged infringer that is reasonably acceptable to Caltech, Licensee shall give timely advance notice to Caltech which, if it so desires, may continue the action or defense. If Caltech controls any action or defense
under Section 8.1 or 8.2, Caltech may not enter into a settlement agreement with a third party without prior written approval of Licensee for any settlement term(s) that may affect any claims that Licensee has or may have against the third
party. 
 8.5 Recoveries. Any amounts paid by third parties to Caltech or Licensee as the result of an
enforcement of the Exclusively Licensed Patent Rights under an action or defense pursuant to Sections 8.1 or 8.2 (including in satisfaction of a judgment or pursuant to a settlement) shall (a) first be applied to reimbursement of professional
fees and expenses (e.g., attorneys’ fees and expert fees) including associated costs incurred by each Party; and (b) second to Caltech and Licensee as follows: 

(i) [***]; 
 (ii) [***]; and

 (iii) [***]. 
 [***]. 

  
 Page 4 of 6

	2.	 All other terms and conditions of the License Agreement, as amended in the First Amendment, that are not
modified or amended pursuant to this Second Amendment shall remain in full force and effect and unaffected hereby. This Second Amendment along with the License Agreement and First Amendment and all applicable exhibits, constitutes the complete
agreement of the Parties concerning the subject matter hereof, and supersedes any other agreements, promises, representations or discussions, written or oral, concerning such subject matter. This Second Amendment may be executed in several
counterparts, all of which taken together shall constitute one single agreement between the Parties. This Second Amendment will be of no force or effect until signed by an authorized representative of each of the Parties. After the Effective Date of
this Second Amendment, every reference in the License Agreement to the “Agreement” shall mean the License Agreement as amended both by the First Amendment and this Second Amendment. 

  
 Page 5 of 6

 In witness whereof, the duly authorized representatives of each of the Parties hereto executed this Second
Amendment. 
  

													
	CALIFORNIA INSTITUTE OF TECHNOLOGY	  		  	AVEDRO, INC.
					
	By:	  	 /s/ Frederic Farina
	  		  	By:	  	 /s/ Reza Zadno

		  	(Authorized Signature)	  		  		  	(Authorized Signature)
	Name:	  	Frederic Farina	  		  	Name:	  	Reza Zadno
	Title:	  	Chief Innovation & Corporate Partnerships Officer	  		  	Title:	  	CEO
					
	Date:	  	10/19/2017	  		  	Date:	  	Oct-19-2017

  
 Page 6 of 6EX-10.18

 Exhibit 10.18 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 
 Framework Agreement 

between 

Medio-Haus-Medizinprodukte GmbH, 

Brunswiker Straße 50, 
 D -
24105 Kiel, 
 hereinafter referred to as “Medio-Haus” 

and 
 Avedro Inc., 

230 3rd Ave., 
 Waltham, MA 02451
USA, 
 hereinafter referred to as “Avedro”. 

Preamble 
 Medio-Haus is
EN ISO 13485: 2003 + AC: 2009 certified. A copy of the relevant certificate is attached hereto marked Exhibit 1. In addition, Medio-Haus holds a certificate of conformity according to Exhibit V of the European Directive 93/42/EC, a copy of
which is attached hereto marked Exhibit 2. 
 On 1 November 2010 the Parties have already concluded a framework agreement on the
supply of the medical product Medio-Cross 0.1 % with Dextran 20 % to Avedro by Medio-Haus. This agreement terminated due to expiration. Nevertheless, the Parties herewith mutually cancel the aforementioned framework agreement dated
1 November 2010 and now enter into the following agreement: 
 Section 1 

 

	(1)	 Medio-Haus undertakes to sell and supply exclusively to Avedro all Medio-Cross products as well as all other
products currently produced by Medio-Haus in the ophthalmologic field for the purpose of Keratoconus treatment with the ingredient Riboflavin, all listed under Exhibit 3 to this Agreement (hereinafter:
“Product(s)”) during the term of this Agreement and in accordance with the terms agreed herein. 

  

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

	(2)	 Avedro hereby undertakes
vis-à-vis Medio-Haus to pay the amount of EUR 500,000.00 for the exclusivity commitment granted under Section 1. Payment shall be made in two
instalments, i.e. in the amount of EUR [***] within [***] following the execution of this Agreement and in the amount of EUR [***] on [***]; in this context, the aforementioned deadlines and dates describe the point in time at which the
respective instalments are to be received by Medio-Haus the latest. 

  

	(3)	 The Parties agree that – irrespective of the provisions under Section 1 paragraph (1) –
Medio-Haus shall remain entitled to continue to sell Products in the amount of maximum of [***] to the ophthalmic clinic [***]. Such right and/or its exercise shall not affect Avedro’s obligations under Section 1 paragraph (2).

  

	(4)	 [***]. 

  

	(5)	 Medio-Haus undertakes to provide Products which are brought to market under the product names of
“Vibex” and/or “Paracel” exclusively to Avedro. For the avoidance of doubt: This shall also apply in the event of an administrative or judicial decision under Section 1 paragraph (4). 

Section 2 
  

	(1)	 No later than [***] prior to the commencement of each calendar quarter, Avedro shall furnish Medio-Haus with a
rolling forecast which sets out Avedro’s prospective Product requirements – broken down into the individual Products listed in Exhibit 3 – for the following [***]. The quantities stipulated in the forecast for the [***] shall
constitute a binding commitment by Avedro to place purchase orders for these quantities on Medio-Haus, and, in the event that Medio-Haus confirms the order, to take delivery of the ordered Products and to pay for same. The quantities contained in
the forecast for the remaining [***] shall constitute a non-binding estimate only. 

  

	(2)	 Product orders shall be provided to Medio-Haus in writing. Medio-Haus will promptly respond to any such orders.
If an order is accepted, a separate agreement based on this Agreement thus being concluded, Medio-Haus will simultaneously provide to Avedro the expected, non-binding delivery date. A delivery period of
approximately [***] is to be expected, unless Medio-Haus has the Product in stock. Medio-Haus shall be obliged to accept all of Avedro’s orders not exceeding the quantities stipulated in Section 4 paragraph (1) of this Agreement
during the mentioned time-period. 

  

	(3)	 Products will only be supplied based on the following procedure: 

Upon Product completion and packaging for shipment, Medio-Haus will notify Avedro accordingly by fax and include the following
annexes: 
  

	 	a)	 An analysis certificate relating to the product batch from which the delivery originates, including a
declaration that the batch was released. A sample document of such a certificate is attached hereto marked Exhibit 4. 

  

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

	 	b)	 A batch-related declaration of conformity from Medio-Haus. A sample certificate is attached hereto marked
Exhibit 5. 

  

	 	c)	 A copy of the analysis certificate including the component ratio analysis, the confirmation of the endotoxins,
freedom from pseudomonas, and sterility, from and by a laboratory commissioned by Medio-Haus, currently [***]. A sample document is attached hereto marked Exhibit 6. 

 

	 	d)	 A copy of the confirmation regarding sterilization with ethylene-oxide in accordance with a recognized and
validated sterilization procedure from and by an entity commissioned by Medio-Haus, currently [***]. A sample document is attached hereto marked Exhibit 7. 

 

	 	e)	 An invoice issued on the date of confirmation that the Products are ready to be shipped. 

Medio-Haus will make the purchased Products available for collection [***] at the relevant registered office of Medio-Haus
pursuant to Section 10 para. 1 sentence 1 German Companies Act. Avedro shall commission and pay a shipping entity for the collection of the Products, and shall, prior to the collection of the Products, in writing or by fax inform Medio-Haus of
the name of the entity that will collect the Products. 
 The price to be paid for the purchased Products shall be due within
[***] upon issuance of the invoice. 
  

	(4)	 The prices are determined by Medio-Haus’ price list applicable at the time whereas potential increases in
prices must be (i) reasonable, demonstrable and non-arbitrary, and (ii) notified in writing in advance with reasonable notice of minimum [***]. 

 

	(5)	 Should Medio-Haus require any information and/or documents from Avedro in connection with the sale and/or
export of the Products to Avedro in order to comply with public obligations, e.g. notification obligations or tax obligations, Avedro shall provide these to Medio-Haus without charge. 

Section 3 
  

	(1)	 The German statutory provisions shall govern the liability of Medio-Haus, including its liability for defects,
unless otherwise provided for in this Agreement. 

  

	(2)	 Medio-Haus gives no warranty that the Product may be certified or licensed for any other purpose than that set
out in the certificates listed in the Preamble hereof, and/or that the Product may be sold or otherwise used. In particular, Medio-Haus shall not be obligated to procure that any certificates and licenses other than those listed in the Preamble
hereof are issued. 

  

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

	(3)	 In the event that Medio-Haus and/or its shareholders, managing directors, employees and/or other
representatives should be held liable by any third party due to and/or in relation to any Products sold and delivered to Avedro, Avedro shall on demand indemnify Medio-Haus from any liability vis-à-vis the claimant. This indemnity shall not affect the existence of any warranty claims, which Avedro may have against Medio-Haus. 

 

	(4)	 Avedro hereby undertakes to Medio-Haus to maintain a liability insurance covering all risks arising from or in
conjunction with the sale and distribution of the Products. Upon request by Medio-Haus, Avedro will provide a copy of the respective insurance policy to Medio-Haus. 

 

	(5)	 Medio-Haus shall only be liable for damage caused intentionally or by gross negligence. Any liability for
indirect or consequential damages, including for loss of profit, is excluded. 

 Section 4 

 

	(1)	 Avedro commits to Medio-Haus to [***] from the product lines under numbers
1.-5. in Exhibit 3 and, in addition, [***] from the product lines under numbers 6.-9. in Exhibit 3. The achievement
of this [***] shall be determined [***], provided that Avedro shall have the right to [***]. 

  

	(2)	 Until and for as long as Avedro has fully complied and complies with its obligations in terms of Section 4
paragraph (1) above, save for Section 1 paragraph (3) above, Medio-Haus will not sell the Products, to any parties or distribution partners other than Avedro. Should Avedro not fully meet its obligations under Section 4 paragraph
(1), its exclusivity commitment pursuant to Section 1 paragraph (1) shall forfeit, i.e. Medio-Haus shall then be entitled to supply the Products to third parties, without any claims by Avedro for reimbursement of the payments made under
Section 1 paragraph (2) and without incurring any other claims by Avedro. 

 Section 5 

 

	(1)	 In the event that the business of Medio-Haus will be transferred to another company by way of a legal
transaction, Medio-Haus undertakes to ensure that the legal successor will assume the rights and obligations under this Agreement. In this case Avedro undertakes to issue any declarations necessary for the access of the legal successor to this
Agreement. Medio-Haus shall ensure in the context of transferring its business to another entity – whether such transfer occurs through an asset deal or the transfer of the majority interest (share deal) – that (i) Avedro is notified
thereof reasonably in advance, however, in no event later than [***] following the execution of the transfer, and (ii) that the company taking over the business continues to perform its supply obligations towards Avedro under Section 1
paragraphs (1) and (5) for any such product orders made before or after the transfer of business, a period of at least [***] after the execution of the transfer on an exclusive supply basis. 

  

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

	(2)	 In the event that Avedro ceases its activities in the relevant business area, or in the event that Avedro
itself starts producing the Products or other products that could replace the Products, or Avedro commissions other entities other than Medio-Haus with the production of such products or purchases such products from other entities, the exclusivity
commitment under Section 1 paragraphs (1) and 4 (2) shall forfeit, i.e. Medio-Haus shall then be entitled to supply the Products to third parties without any claims by Avedro for reimbursement of the payments made under Section 1 (2)
and without incurring any other claims by Avedro. Notwithstanding the provisions set forth in this Section 5 (2), Avedro, however, shall be entitled to produce by itself in the USA ophthalmologic Products with the active pharmaceutical
ingredient Riboflavin on the basis of an own respective US FDA GMP admission in accordance with the rules provided thereunder, provided such products are solely marked and used in the USA as well as in countries in which a US FDA GMP admission is
required and a CE marking not sufficient, and provided the name MedioCross or any confusingly similar name will not be used for such Products. Avedro shall bear the burden to prove the compliance with the requirements set forth above.

  

	(3)	 Avedro shall not be entitled to assign any rights arising out of and/or in connection with this Agreement to
third parties or transfer them in any other way to legal successors. Avedro shall also not be entitled to permit third parties to exercise rights arising from this Agreement. Should Avedro breach the terms of this Section 5 paragraph (3), the
exclusivity commitments under Section 1 paragraphs (1) and 4 (2) shall forfeit – regardless of the invalidity of the assignment to a third party –, i.e. Medio-Haus shall then be entitled to supply the Products to third parties
without any claims by Avedro for reimbursement of the payments made under Section 1 paragraph (2) and without incurring any other claims by Avedro. In the event that a third party acquires the majority of votes or of shares in Avedro,
Avedro shall have the right to terminate this Agreement with [***] prior notice. In case Avedro terminates hereunder, Avedro shall neither have any claims for reimbursement of the payments made under Section 1 paragraph (2), nor for any other
compensation claims against Medio-Haus. 

 Section 6 

 

	(1)	 This Agreement has a term of 15 years and shall terminate automatically without further notice upon expiry of
this term. In the event of such termination by expiry under this Section 6 paragraph (1) sentence 1, Avedro shall neither have any claims for reimbursement of the payments made under Section 1 paragraph (2), nor for any other
compensation claims against Medio-Haus. 

  

	(2)	 To the extent this Agreement does not contain any deviating provisions, it is only terminable otherwise for
important reason (“Kündigung aus wichtigem Grund”). In the event of a termination for important reason Avedro shall have a right for reimbursement of the payments made under Section 1 paragraph (2) only in the event
that Medio-Haus is responsible for the important reason. 

 Section 7 

 

	(1)	 Each party acknowledges and agrees that its general terms and conditions (AGB) shall neither apply to
this Agreement, nor the purchase orders concluded and/or to be concluded between the Parties in terms thereof. 

  

	(2)	 This Agreement and any purchase orders concluded on the basis thereof, and/or any disputes arising therefrom
and/or in conjunction therewith, shall be exclusively governed and be subject to the law of the Federal Republic of Germany. The application of the United Nations Convention on Contracts for the International Sale of Goods (CISG), dated
11 April 1980, and the provisions of the private international law (conflict of laws) are specifically excluded. 

  

	(3)	 Place of jurisdiction for any and all disputes arising from and/or in conjunction with this framework agreement
and/or any and all agreements concluded on the basis thereof shall be Kiel, Federal Republic of Germany. 

  

	(4)	 The language of this framework agreement is German. 

Section 8 
  

	(1)	 This Agreement shall replace and comes in lieu of the preliminary agreement between the Parties as of
May 21, 2014. This Agreement contains all the express provisions agreed on by the parties with regard to the subject matter hereof, and collateral or other agreements related hereto do not exist. Amendments to this Agreement shall be effected
in writing (Schriftform). This also applies to the waiver of the written form requirement. 

  

	(2)	 The invalidity of individual provisions of this Agreement does not affect the validity of the remaining
provisions and the existence of this Agreement. 

  

							
	Kiel, June 12, 2014	  		  	Waltham, June 12, 2014	  	
				
	 /s/ Thomas Steffens
	  		  	 /s/ David Muller
	  	
	                    Medio-Haus	  		  	                    Avedro	  	

  

 [***] = TWO (2) PAGES OF CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT 10.16, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

[***] 

  

 3 
 List of
products ( 2014-06-07 ): 
 1. MedioCross D 
 2. MedioCross
H 
 3. MedioCross M 
 4. MedioCross TE 

5. MedioCross L 
 6. Vibex 

7. Vibex XTRA 
 8. Vibex Rapid 

9. Paracel 
  
  

  
 . 

 [***] = EIGHT (8) PAGES OF CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT 10.16, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

[***] 

  
 9.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}]]